Search

Your search keyword '"Kawakami, H"' showing total 3,125 results

Search Constraints

Start Over You searched for: Author "Kawakami, H" Remove constraint Author: "Kawakami, H"
3,125 results on '"Kawakami, H"'

Search Results

2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

4. Update on the angular resolution of GRAPES-3 experiment based on Moon shadow analysis

5. Updated results on the cosmic ray energy spectrum and composition from the GRAPES-3 experiment

6. Highlights of the results from the GRAPES-3 experiment

11. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

12. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

13. Computer-assisted surgery with markerless augmented reality for the surgical removal of mandibular odontogenic cysts: report of two clinical cases.

15. The significance of excessive supraventricular ectopic activity immediately after catheter ablation in the risk stratification for late recurrence of atrial fibrillation

17. The Swift Ultra-Violet/Optical Telescope

20. The XMM-Newton Optical/UV Monitor Telescope

24. 1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)

25. 1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)

26. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

27. 440TiP TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRC

28. 1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma

30. 522P Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)

31. 518MO Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)

34. P-99 A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G

35. SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)

36. P-35 An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study

37. O-3 Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648

38. P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study

39. P-15 Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

40. SO-19 Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer

Catalog

Books, media, physical & digital resources